MCID: TCK001
MIFTS: 54

Tick-Borne Encephalitis

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Tick-Borne Encephalitis

MalaCards integrated aliases for Tick-Borne Encephalitis:

Name: Tick-Borne Encephalitis 12 76 53 59 15 73
Siberian Tick-Borne Encephalitis 12 73
Western European Tick-Borne Encephalitis 12
Russian Spring-Summer Encephalitis 12
Encephalitis, Far Eastern Russian 73
Encephalitis, Central European 73
Central European Encephalitis 12
West-Siberian Encephalitis 12
Encephalitis, Tick-Borne 44
Encephalitis Tick-Borne 55
Taiga Encephalitis 12
Far Eastern Tbe 12
Tbe 59

Characteristics:

Orphanet epidemiological data:

59
tick-borne encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050175
ICD10 33 A84.1
ICD9CM 35 063.2
MeSH 44 D004675
SNOMED-CT 68 16901001
Orphanet 59 ORPHA297
MESH via Orphanet 45 D004675
UMLS via Orphanet 74 C0014061
ICD10 via Orphanet 34 A84.0 A84.1 A84.8 more

Summaries for Tick-Borne Encephalitis

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain, has material basis in Tick-borne encephalitis virus, which is transmitted by Ixodes ticks. The infection has symptom drowsiness, has symptom confusion, has symptom sensory disturbances, and has symptom paralysis.

MalaCards based summary : Tick-Borne Encephalitis, also known as siberian tick-borne encephalitis, is related to encephalitis and herpes simplex encephalitis, and has symptoms including drowsiness, confusion and sensory disturbances. An important gene associated with Tick-Borne Encephalitis is SCRIB (Scribbled Planar Cell Polarity Protein), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Formaldehyde and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include brain, brain and testes, and related phenotype is neoplasm.

Wikipedia : 76 Tick-borne encephalitis (TBE) is a viral infectious disease involving the central nervous system. The... more...

Related Diseases for Tick-Borne Encephalitis

Diseases related to Tick-Borne Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 encephalitis 30.5 CCR5 CD209 CXCL10 SCRIB TLR3
2 herpes simplex encephalitis 30.3 CXCL11 TLR3
3 hemorrhagic fever 30.3 ALB CD209 IL10
4 west nile virus 30.0 CCR5 CD209 OAS1 TLR3
5 japanese encephalitis 29.8 CD209 CXCL10 TLR3
6 multiple sclerosis 28.3 CCR5 CXCL10 CXCL11 IL10
7 powassan encephalitis 11.2
8 cow milk allergy 10.6 CCR5 IL10
9 orofacial granulomatosis 10.6 CCR5 IL10
10 aging 10.4
11 west nile encephalitis 10.3 OAS1 OAS3
12 chronic graft versus host disease 10.3 ALB IL10
13 extrinsic cardiomyopathy 10.3 IL10 TLR3
14 fascioliasis 10.3 ALB IL10
15 human granulocytic anaplasmosis 10.3
16 ehrlichiosis 10.3
17 hand, foot and mouth disease 10.3 IL10 OAS1
18 mucocutaneous leishmaniasis 10.3 CCR5 IL10 TLR3
19 dengue virus 10.3
20 thrombocytopenia 10.3
21 lipoid nephrosis 10.2 ALB IL10
22 hepatitis e 10.2 ALB TLR3
23 louping ill 10.2
24 kyasanur forest disease 10.2
25 lyme disease 10.2
26 tick infestation 10.2
27 neuronitis 10.2
28 venezuelan equine encephalitis 10.2
29 transmitted_by 10.2
30 yellow fever 10.2 CCR5 OAS1
31 microphthalmia with limb anomalies 10.2 OAS1 OAS3
32 polyradiculoneuropathy 10.2 ALB IL10
33 meningoencephalitis 10.1
34 crimean-congo hemorrhagic fever 10.1
35 vaccinia 10.1
36 herpes simplex 10.1
37 meningitis 10.1
38 hemorrhagic fever with renal syndrome 10.1 ALB IL10
39 acquired immunodeficiency syndrome 10.0 ALB CCR5 IL10
40 neurosyphilis 10.0 CXCL10 IL10
41 keratoconjunctivitis sicca 10.0 ALB IL10
42 myositis 10.0
43 dengue disease 10.0
44 hepatitis 10.0
45 hepatitis b 10.0
46 zika fever 10.0
47 mumps 10.0
48 st. louis encephalitis 10.0
49 optic neuritis 10.0
50 rift valley fever 10.0

Graphical network of the top 20 diseases related to Tick-Borne Encephalitis:



Diseases related to Tick-Borne Encephalitis

Symptoms & Phenotypes for Tick-Borne Encephalitis

Symptoms:

12
  • drowsiness
  • confusion
  • sensory disturbances
  • paralysis

MGI Mouse Phenotypes related to Tick-Borne Encephalitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 ALB CCR5 IL10 SCRIB TLR3

Drugs & Therapeutics for Tick-Borne Encephalitis

Drugs for Tick-Borne Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
4 Antibodies Phase 4,Not Applicable
5 Immunoglobulins Phase 4,Not Applicable
6 Pharmaceutical Solutions Phase 4
7 Anti-Infective Agents Phase 4,Not Applicable
8 Disinfectants Phase 4
9 Blood Substitutes Phase 4
10 Plasma Substitutes Phase 4
11 Polygeline Phase 4
12
Lactitol Investigational Phase 3 585-86-4 3871
13
Doxycycline Approved, Investigational, Vet_approved Not Applicable 564-25-0 54671203
14
Granisetron Approved, Investigational Not Applicable 109889-09-0 3510
15
Acyclovir Approved 59277-89-3 2022
16
Ceftriaxone Approved 73384-59-5 5479530 5361919
17
Dopamine Approved 51-61-6, 62-31-7 681
18 Anti-Bacterial Agents Not Applicable
19 Antibiotics, Antitubercular Not Applicable
20 Antiemetics Not Applicable
21 Antimalarials Not Applicable
22 Antiparasitic Agents Not Applicable
23 Antiprotozoal Agents Not Applicable
24 Antipyretics Not Applicable
25 dipyrone Not Applicable
26 Antiviral Agents
27 Autonomic Agents
28 Dopamine Agents
29 Dopamine Antagonists
30 Gastrointestinal Agents
31 Neurotransmitter Agents
32 Peripheral Nervous System Agents

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
2 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
3 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Completed NCT01710189 Phase 4 TicoVac
4 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Completed NCT00161967 Phase 4
5 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
6 TBE Seropersistence up to 10 Years After First Booster in Adults Completed NCT01582698 Phase 4
7 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) Completed NCT00894686 Phase 4
8 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Completed NCT00503529 Phase 4
9 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
10 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
11 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
12 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Completed NCT00311493 Phase 4
13 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Completed NCT00311441 Phase 4
14 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
15 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® Completed NCT02511587 Phase 4
16 TBE Vaccination in Allergic Patients Completed NCT02511535 Phase 4
17 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Active, not recruiting NCT03294135 Phase 4
18 Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Completed NCT01361776 Phase 2, Phase 3
19 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children Completed NCT00840801 Phase 3
20 FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years Completed NCT00161876 Phase 3
21 Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years Completed NCT00161746 Phase 2, Phase 3
22 Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR Completed NCT00161824 Phase 3
23 Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Completed NCT00161863 Phase 3
24 Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines Completed NCT00644059 Phase 3
25 New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Active, not recruiting NCT02318069 Phase 2, Phase 3
26 Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine Unknown status NCT00890422 Phase 2
27 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Completed NCT00161798 Phase 2
28 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Completed NCT00161772 Phase 2
29 FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years Completed NCT00161889 Phase 2
30 FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years Completed NCT00161850 Phase 2
31 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients Active, not recruiting NCT01991067 Phase 2
32 Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) Terminated NCT01031537 Phase 2
33 Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Completed NCT00118924 Phase 1
34 Postencephalitic Symptoms After Tick Borne Encephalitis Unknown status NCT00941590
35 Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis Completed NCT02275741
36 Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children Completed NCT00163618
37 Tick-borne Encephalitis and Positive Borrelial Antibodies Recruiting NCT02463942 Not Applicable Doxycycline;Symptomatic therapy
38 Aseptic Meningoencephalitis in Slovenia Recruiting NCT02328469 symptomatic therapy;Ceftriaxone or Doxycycline;Acyclovir

Search NIH Clinical Center for Tick-Borne Encephalitis

Cochrane evidence based reviews: encephalitis, tick-borne

Genetic Tests for Tick-Borne Encephalitis

Anatomical Context for Tick-Borne Encephalitis

The Foundational Model of Anatomy Ontology organs/tissues related to Tick-Borne Encephalitis:

19
Brain

MalaCards organs/tissues related to Tick-Borne Encephalitis:

41
Brain, Testes, T Cells, Neutrophil, Nk Cells, B Cells, Liver

Publications for Tick-Borne Encephalitis

Articles related to Tick-Borne Encephalitis:

(show top 50) (show all 701)
# Title Authors Year
1
The intrathecal expression and pathogenetic role of Th17 cytokines and CXCR2-binding chemokines in tick-borne encephalitis. ( 29678185 )
2018
2
Tick-Borne Encephalitis Virus Nonstructural Protein NS5 Induces RANTES Expression Dependent on the RNA-Dependent RNA Polymerase Activity. ( 29760190 )
2018
3
Development of a serodiagnostic IgM-ELISA for tick-borne encephalitis virus using subviral particles with strep-tag. ( 29960872 )
2018
4
First detection of tick-borne encephalitis virus RNA in clinical specimens of acutely ill patients in Hungary. ( 29373305 )
2018
5
Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017. ( 29386094 )
2018
6
Complete Genomic Characterization of Three Tick-Borne Encephalitis Viruses Detected Along the China-North Korea Border, 2011. ( 29742014 )
2018
7
Tick-borne encephalitis virus, Borrelia burgdorferi sensu lato, Borrelia miyamotoi, Anaplasma phagocytophilum and Candidatus Neoehrlichia mikurensis in Ixodes ricinus ticks collected from recreational islands in southern Norway. ( 29678403 )
2018
8
Viperin restricts Zika virus and tick-borne encephalitis virus replication by targeting NS3 for proteasomal degradation. ( 29321318 )
2018
9
Probing chemical space of tick-borne encephalitis virus reproduction inhibitors with organoselenium compounds. ( 29709065 )
2018
10
Mechanisms of Antiviral Activity of the Polyphenol Complex from Seagrass of the Zosteraceae Family against Tick-Borne Encephalitis Virus. ( 29797124 )
2018
11
Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody. ( 29382836 )
2018
12
Tick-Borne Encephalitis Virus: A Structural View. ( 29958443 )
2018
13
Erratum for Panayiotou et al., &amp;quot;Viperin Restricts Zika Virus and Tick-Borne Encephalitis Virus Replication by Targeting NS3 for Proteasomal Degradation&amp;quot;. ( 29844247 )
2018
14
Serologic Evidence of Tick-Borne Encephalitis Virus Infection in a Patient with Suspected Lyme Disease in Japan. ( 29848409 )
2018
15
Borrelia burgdorferi sl and tick-borne encephalitis virus coinfection in Eastern France. ( 29449048 )
2018
16
Meningoencephaloradiculitis following infection with tick borne encephalitis virus: case report and review of the literature. ( 29313244 )
2018
17
The long-term outcome of tick-borne encephalitis in Central Europe. ( 29275872 )
2018
18
Exposure to West Nile virus and tick-borne encephalitis virus in dogs in Spain. ( 29322674 )
2018
19
Diagnosing tick-borne encephalitis: a re-evaluation of notified cases. ( 29188467 )
2018
20
Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias. ( 29673942 )
2018
21
Comparative genome analysis of Alkhumra hemorrhagic fever virus with Kyasanur forest disease and tick-borne encephalitis viruses by the in silico approach. ( 29745301 )
2018
22
A new subtype of eastern tick-borne encephalitis virus discovered in Qinghai-Tibet Plateau, China. ( 29691370 )
2018
23
Virus RNA Load in Patients with Tick-Borne Encephalitis, Slovenia. ( 29912706 )
2018
24
A novel locus on mouse chromosome 7 that influences survival after infection with tick-borne encephalitis virus. ( 29976152 )
2018
25
Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection<i>In</i><i>Vitro</i>and in a Mouse Model. ( 29435494 )
2018
26
3'-O-Substituted 5-(perylen-3-ylethynyl)-2'-deoxyuridines as tick-borne encephalitis virus reproduction inhibitors. ( 29859999 )
2018
27
Brain perfusion alterations in tick-borne encephalitis-preliminary report. ( 29337197 )
2018
28
A matrix metalloproteinase 9 (MMP9) gene single nucleotide polymorphism is associated with predisposition to tick-borne encephalitis virus-induced severe central nervous system disease. ( 29496490 )
2018
29
A cluster of two human cases of tick-borne encephalitis (TBE) transmitted by unpasteurised goat milk and cheese in Germany, May 2016. ( 29667575 )
2018
30
Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10a8^years antibody persistence. ( 29397225 )
2018
31
Fatal Tick-Borne Encephalitis Virus Infections Caused by Siberian and European Subtypes, Finland, 2015. ( 29664395 )
2018
32
A database of human genes and a gene network involved in response to tick-borne encephalitis virus infection. ( 29297316 )
2017
33
Analysis of tick-borne encephalitis virus-induced host responses in human cells of neuronal origin and interferon-mediated protection. ( 28786780 )
2017
34
Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules. ( 28770638 )
2017
35
Tick-borne encephalitis in Japan, Republic of Korea and China. ( 28928417 )
2017
36
Human Tick-Borne Encephalitis, the Netherlands. ( 27938522 )
2017
37
Comparative analysis of genomes of tick-borne encephalitis virus strains isolated from mosquitoes and ticks. ( 29323844 )
2017
38
Geographical Environment Factors and Risk Assessment of Tick-Borne Encephalitis in Hulunbuir, Northeastern China. ( 28587151 )
2017
39
COMPARISON BETWEEN PROTON MAGNETIC RESONANCE SPECTROSCOPY FINDINGS IN DOGS WITH TICK-BORNE ENCEPHALITIS AND CLINICALLY NORMAL DOGS. ( 27714889 )
2017
40
The increased concentration of macrophage migration inhibitory factor in serum and cerebrospinal fluid of patients with tick-borne encephalitis. ( 28646884 )
2017
41
Tick-Borne Encephalitis in Sheep, Romania. ( 29148377 )
2017
42
Tick-borne encephalitis in a naturally infected sheep. ( 28830430 )
2017
43
Necessity of a Surveillance System for Tick-borne Encephalitis. ( 28540160 )
2017
44
Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention. ( 29670929 )
2017
45
Molecular Detection and Serological Evidence of Tick-Borne Encephalitis Virus in Serbia. ( 29064333 )
2017
46
Transcriptional Immunoprofiling at the Tick-Virus-Host Interface during Early Stages of Tick-Borne Encephalitis Virus Transmission. ( 29250492 )
2017
47
Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin. ( 27884572 )
2017
48
A comparative analysis on the physicochemical properties of tick-borne encephalitis virus envelope protein residues that affect its antigenic properties. ( 28625666 )
2017
49
Report of the 19th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) - TBE in a changing world. ( 28918352 )
2017
50
Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection. ( 29263866 )
2017

Variations for Tick-Borne Encephalitis

Expression for Tick-Borne Encephalitis

Search GEO for disease gene expression data for Tick-Borne Encephalitis.

Pathways for Tick-Borne Encephalitis

Pathways related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 CCR5 CD209 CXCL10 IFNL3 IL10 OAS1
2
Show member pathways
13.07 CCR5 CXCL10 CXCL11 IL10 TLR3
3
Show member pathways
12.91 CCR5 CXCL10 IFNL3 IL10 OAS1 OAS3
4 12.18 CXCL10 IL10 OAS1 TLR3
5
Show member pathways
12.15 IFNL3 IL10 OAS1 OAS3
6
Show member pathways
12.04 CD209 CXCL10 OAS1 OAS3 TLR3
7
Show member pathways
11.95 CXCL10 CXCL11 IL10 OAS1 OAS3 TLR3
8 11.73 OAS1 OAS3 TLR3
9
Show member pathways
11.64 CCR5 CXCL10 CXCL11
10 11.08 CXCL10 OAS1
11 11.03 CXCL10 CXCL11
12 11.02 CCR5 CXCL10 IL10
13
Show member pathways
10.84 IFNL3 OAS1

GO Terms for Tick-Borne Encephalitis

Cellular components related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 ALB CXCL10 CXCL11 IFNL3 IL10 OAS3
2 extracellular region GO:0005576 9.17 ALB CD209 CXCL10 CXCL11 IFNL3 IL10

Biological processes related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 CD209 OAS1 OAS3 TLR3
2 regulation of signaling receptor activity GO:0010469 9.85 CXCL10 CXCL11 IFNL3 IL10
3 innate immune response GO:0045087 9.83 CD209 IFNL3 OAS1 OAS3 TLR3
4 cytokine-mediated signaling pathway GO:0019221 9.78 CCR5 CXCL10 IFNL3 IL10
5 response to lipopolysaccharide GO:0032496 9.77 CXCL10 CXCL11 IL10
6 chemotaxis GO:0006935 9.73 CCR5 CXCL10 CXCL11
7 inflammatory response GO:0006954 9.72 CCR5 CXCL10 CXCL11 IL10 TLR3
8 cellular response to lipopolysaccharide GO:0071222 9.71 CCR5 CXCL10 IL10
9 chemokine-mediated signaling pathway GO:0070098 9.63 CCR5 CXCL10 CXCL11
10 negative regulation of mitotic cell cycle GO:0045930 9.6 IL10 SCRIB
11 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.58 CXCL10 CXCL11
12 positive regulation of leukocyte chemotaxis GO:0002690 9.57 CXCL10 CXCL11
13 defense response GO:0006952 9.56 CCR5 CXCL10 CXCL11 TLR3
14 negative regulation of viral genome replication GO:0045071 9.54 IFNL3 OAS1 OAS3
15 positive regulation of cAMP-mediated signaling GO:0043950 9.52 CXCL10 CXCL11
16 positive regulation of cAMP metabolic process GO:0030816 9.51 CXCL10 CXCL11
17 T cell chemotaxis GO:0010818 9.49 CXCL10 CXCL11
18 response to virus GO:0009615 9.46 CXCL10 OAS1 OAS3 TLR3
19 immune response GO:0006955 9.43 CCR5 CXCL10 CXCL11 IL10 OAS1 OAS3
20 regulation of ribonuclease activity GO:0060700 9.4 OAS1 OAS3
21 defense response to virus GO:0051607 9.02 CXCL10 IFNL3 OAS1 OAS3 TLR3

Molecular functions related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.43 OAS1 OAS3 TLR3
2 CXCR chemokine receptor binding GO:0045236 9.32 CXCL10 CXCL11
3 cytokine activity GO:0005125 9.26 CXCL10 CXCL11 IFNL3 IL10
4 CXCR3 chemokine receptor binding GO:0048248 9.16 CXCL10 CXCL11
5 2-5-oligoadenylate synthetase activity GO:0001730 8.62 OAS1 OAS3

Sources for Tick-Borne Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....